Stock CRBU CARIBOU BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
3.76 USD -2.34% Intraday chart for Caribou Biosciences, Inc. -3.84% -34.38%
Apr. 05 Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday MT
Apr. 04 Caribou Gets FDA Clearance For Phase 1 Testing of CB-010 Cell Therapy in Lupus Patients MT

Business Summary

Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity. Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate.

Number of employees: 158

Sales per Business

USD in Million2022Weight2023Weight Delta
Allogeneic CAR-T and CAR-NK Cell Therapies
100.0 %
14 100.0 % 34 100.0 % +148.91%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
95.0 %
13 96.0 % 33 95.0 % +146.34%
Rest of World
5.0 %
1 4.0 % 2 5.0 % +211.50%

Managers

Managers TitleAgeSince
Rachel Haurwitz FOU
 Founder 38 11-10-27
Jason O’Byrne DFI
 Director of Finance/CFO 54 21-02-08
Steven Kanner CTO
 Chief Tech/Sci/R&D Officer 65 17-05-31
Timothy Kelly CTO
 Chief Tech/Sci/R&D Officer 55 Jan. 06
Reigin Zawadzki HRO
 Human Resources Officer - 23-09-26
Cindy Hayashi HRO
 Human Resources Officer - 16-07-31
Ryan Fischesser AUD
 Comptroller/Controller/Auditor - -
Elaine Alambra LAW
 General Counsel - -
Ruhi Khan PRN
 Corporate Officer/Principal - 21-11-07
Barbara McClung LAW
 General Counsel 69 15-03-31

Members of the board

Members of the board TitleAgeSince
Andrew Guggenhime BRD
 Director/Board Member 55 21-03-31
Scott Braunstein BRD
 Director/Board Member 60 21-05-31
Dara Richardson-Heron BRD
 Director/Board Member 59 21-11-07
Rachel Haurwitz FOU
 Founder 38 11-10-27
Natalie Sacks BRD
 Director/Board Member 59 18-04-30
David Johnson BRD
 Director/Board Member 55 22-05-10
Ran Zheng BRD
 Director/Board Member 60 21-09-23
Nancy Whiting BRD
 Director/Board Member 51 21-08-23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 90,314,501 81,153,923 ( 89.86 %) 0 89.86 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
7.341 %
6,629,990 7.341 % 34 M $
PFM Health Sciences LP
7.176 %
6,480,764 7.176 % 33 M $
Avidity Partners Management LP
7.042 %
6,360,212 7.042 % 33 M $
STATE STREET CORPORATION
5.669 %
5,119,666 5.669 % 26 M $
PFIZER, INC.
5.193 %
4,690,431 5.193 % 24 M $
Point72 Asset Management LP
4.908 %
4,432,602 4.908 % 23 M $
Vanguard Fiduciary Trust Co.
4.387 %
3,962,044 4.387 % 20 M $
Point72 Asset Management LP
3.899 %
3,521,376 3.899 % 18 M $
Rachel Haurwitz
3.884 %
3,508,095 3.884 % 18 M $
Oppenheimer Asset Management (Alkeon Subfiler)
3.447 %
3,113,564 3.447 % 16 M $

Company contact information

Caribou Biosciences, Inc.

2929 7th Street Suite 105

94710, Berkeley

+

http://www.cariboubio.com
address Caribou Biosciences, Inc.(CRBU)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per region

Ratings for Caribou Biosciences, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
3.76 USD
Average target price
20 USD
Spread / Average Target
+431.91%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CARIBOU BIOSCIENCES, INC. Stock Caribou Biosciences, Inc.
-34.38% 340M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.12% 42.59B
MODERNA, INC. Stock Moderna, Inc.
+6.77% 40.65B
LONZA GROUP AG Stock Lonza Group AG
+47.98% 40.57B
CELLTRION, INC. Stock Celltrion, Inc.
-11.96% 26.77B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+6.01% 24.81B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.92% 18.17B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.63% 11.7B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.16% 12.05B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+7.30% 11.1B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CRBU Stock
  4. Company Caribou Biosciences, Inc.